Roadmap of HIV/TB Sessions

**SUNDAY, 23 JULY 2017**

**Waiting isn’t an Option: How to Survive Advanced HIV**
Non-Commercial Satellite – SUSA09
Time: 12:30 - 14:30  Venue: Maillot Room
Organizers: Médecins Sans Frontieres
This satellite will discuss how continued CD4 at initiation, rapid diagnostics tools and treatments, faster switches and the adoption of Advanced HIV guidelines can not only treat advanced HIV, but also help prevent it at community and primary healthcare level. It will also include a presentation by Nathan Ford on WHO’s new Advanced Disease Guidelines: New concepts and missing evidence.

**What’s in HIV treatment: WHO guidelines on advanced HIV disease, accelerated ART initiation and transitioning to new ARV regimens**
Non-Commercial Satellite – SUSA13
Time: 14:45 - 16:45  Venue: Bordeaux Amphitheatre
Organizers: World Health Organization
At IAS 2017, WHO is releasing new guidelines on advanced HIV disease, recommending that people who are “sickest” and with advanced HIV disease should be provided with a defined package of care including screening, treatment and prophylaxis for major opportunistic infections (such as TB and cryptococcal disease), rapid initiation of ART and intensified treatment adherence support.

**MONDAY, 24 JULY 2017**

**Integrating Diagnostic Services at Point of Care**
Corporate Satellite – MOSA04
Time: 07:00 - 08:30  Venue: Room 242
Organizers: Cepheid

A simple molecular technology like GeneXpert that can be used at point-of-care delivering on-demand timely results, can help to close gaps in treatment initiation and linkage to care, that currently lead to poorer health outcomes, higher treatment costs, and further spread of disease. This satellite will discuss the possibilities of using the same GeneXpert platform to perform different tests such as HIV, TB, HCV, CT/NG and HPV.

**Tuberculosis in a Time of HIV**

**Oral Abstract Session Track B – MOAB04**
Time: 16:30 – 18:00  Venue: Maillot Room
Co-Chairs: Diane Havlir, USA and Robin Wood, South Africa

16:30 MOAB0407: Introductory Remarks. Marijke Wijnroks, Switzerland
16:35 MOAB0401: Gaps and opportunities in policy and practice in 20 countries with the highest Burden of HIV-associated TB  
Presenter: A Baddeley, World Health Organization, Switzerland
16:49 MOAB0402: Genomic epidemiology of extensively drug-resistant TB in KwaZulu-Natal, South Africa: demographic expansion and genetic determinants of epidemiologic success  
In a high HIV prevalence setting. Presenter: T S. Brown, USA
17:03 MOAB0403: Incidence of tuberculosis in the first year of antiretroviral treatment in West-African HIV-infected adults. Presenter: B Tchakounte Youngui, France
17:17 MOAB0404: Time to treatment initiation of drug-resistant TB is delayed in a South African Prospective cohort. Presenter: B J Sullivan, USA
17:31 MOAB0405: High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland. Presenter: J Pathmanathan, USA
17:45 MOAB0406: Feasibility of using determine-TB LAM test in HIV-infected adults in programmatic conditions. Presenter: S C Mathabire, France

**TUESDAY, 25 JULY 2017**

**Late Breaker Poster Discussion Session**
Poster Discussion Session: TUPDB02
Time: 13:00 – 14:00  Venue: Havana Amphitheater
Co-Chairs: J Rockstroh, Germany and C Delaughter, France
13:15 TUPDB0204LB: Universal sputum testing vs. symptom-based testing for TB in HIV-infected pregnant women: a cluster-randomized implementation trial in South Africa. Presenter: N Martinson, South Africa
TUESDAY, 25 JULY 2017 continued

Treat All: How to Make It Happen and Can We Afford It?
Oral Abstract Session Track D – Implementation Science: **TUAD01**
Time: 14:30 – 16:00  Venue: Maillot Room
Co-Chairs: G Hirnschall, WHO, Switzerland and S Abdool Karim, South Africa

15:17 TUAD0104: Generic treatments for HIV, HBV, HCV, TB could be mass produced for <$90 per patient.  Presenter : D Gotham, UK

Ending AIDS through Research Training and Capacity Building in Low- and Middle-income Countries: Lessons Learned and Future Directions.
Symposia Session: **TUSY05**
Time: 16:30 – 18:00  Venue: Maillot Room
Co-Chairs: P Kilmarx, USA and Q Abdool Karim, South Africa

16:40 Advances in care and treatment of AIDS, TB, and other opportunistic infections through research capacity building in Haiti.  Presenter : JW Pape, Haiti

Breaking Barriers, Building Bridges: The Dutch Approach to AIDS 2018 Combining Science, Civil Society and Government Efforts
Non-Commercial Satellite: **TUSA12**
Time: 18:30 – 20:30  Venue: Room 241
Co-Chairs: L-G Bekker, South Africa, P Reiss, Netherlands

19:00 An integrated approach to HIV, TB and viral hepatitis: the way forward
Presenter: L Mendão, Portugal

Bringing the Test to the Patient: Results from the Early Routine Use Of Point-of-Care HIV Testing in Resource-limited Settings
Non-Commercial Satellite: **TUSA13**
Time: 18:30 – 20:30  Venue: Room 242
Co-Chairs: S de Lussigny, Switzerland and A Reinisch, Switzerland

18:54 Leveraging excess GeneXpert capacity to integrate HIV and TB testing services: a case study from Zimbabwe.  Presenter: R Simbi, Zimbabwe

Side Event
Time: 18:00 – 19:30  Venue: Méridien Etoile Hotel, Latitude Meeting Room, 81 Boulevard Gouvion Saint-Cyr, Paris
Organizer: World Health Organization
Co-Chairs: G Hirnschall, WHO, Switzerland and Ambassador Deborah L Birx, USA

In preparation for the first WHO Ministerial Conference on ending TB in a Sustainable Development Era, WHO is convening a Consultation at the 9th International AIDS Society Conference on HIV Science to elicit input and feedback for actions needed to galvanize political momentum to eliminate TB deaths among people living with HIV.

18:00 Welcome and introduction
18:05 Eliminating HIV-associated TB deaths: what does it mean?
Presenter H Getahun, WHO, Switzerland
18:20 Research gaps for eliminating TB deaths among people living with HIV.
Presenter: G Churchyard, South Africa
18:35 Panel Discussion: How to galvanize political commitment for eliminating HIV-associated TB deaths?
Panellists: Y Pillay, South Africa
            M Murenga, Kenya
            S Hade, USA
            H Ayles, Zambia
            L Marmora, Switzerland

19:00 Discussion
19:30 Closing
WEDNESDAY, 26 JULY 2017

Coinfections Associated with High Mortality in Severely Immunocompromised HIV Patients
Non-Commercial Satellite: WESA04
Time: 07:00 – 08:30  Venue: Room 242
Chair: A Kambugu, Uganda

This symposium will highlight recent advances in HIV-associated tuberculosis and HIV-cryptococcal co-infections, showcase EDCTP/ANRS-funded projects and present the funding strategy in this area. The following themes will be covered: (1) quantitative diagnostics, (2) advances in efficacious, low toxicity treatments and (3) implementation of treatment algorithms to reduce mortality.

Plenary Session

Plenary Session WEPL01
Time 08:45-10:30  Venue: Grand Amphitheater
Co-chairs: Marijke Wijnroks, Switzerland and Valerie Pecresse, France

08:45 IAS TB/HIV Research Prizes: annual prizes
Presenters: H Getahun, WHO, Switzerland and A Pozniak, UK

Integration of HIV with Other Care Services

Symposia Session: WESY02
Time: 11:00 – 12:30  Venue: Bordeaux Ambitheatre
Co-Chairs: M Doherty WHO, Switzerland and J-P Daulouede, France

This session highlights successful models for integration of HIV care with other important health services, including hepatitis C, substance abuse and mental health treatment, reproductive /maternal/child health, non-communicable diseases and management of tuberculosis. It will discuss the clinical and economic impact of integrated care models, including the tradeoffs between “horizontal” versus “vertical” service provision.

Tuberculosis in Europe: The Impact of Migration

Workshop: WEWS01
Time: 11:00 – 12:30  Venue: Room 242
Co-facilitators: C Oprea, Romania and J Hakim, Zimbabwe

This workshop, intended for clinicians, the public health community and investigators interested in TB, addresses the epidemiological and clinical aspects of TB in Europe, with a special focus on the impact of migration in this regional epidemic and on the specific situation in Eastern Europe. Additionally, new diagnostic tools and new treatment options for TB are explored. Participants at this workshop can learn about the challenges linked to TB for migrant populations and how this can be addressed epidemiologically and clinically.

11:00 Introduction
11:10 Epidemiological and clinical aspects of TB in Eastern Europe.
Presenter: D Podlekareva, Denmark
11:20 The Impact of migration of TB epidemiology in Europe
Presenter: D Zenner, UK
11:30 TB screening and case finding among migrants
Presenter: A Hristea, Romania
11:40 New methods and drugs for TB diagnosis and treatment: an update
Presenter: F-X Blanc, France

Opportunistic Infections and AIDS-defining Cancers: Can We Do Better?

Poster Discussion Session WEPDB01
Time: 13:00 – 14:00  Venue: Maillot Room
Co-Chairs: A Grulich, Australia and B Crabtree-Ramirez, Mexico

13:25 Screening for tuberculosis with Xpert MTB/RIF versus fluorescent microscopy among people newly diagnosed with HIV in rural Malawi: a cluster-randomized trial
Presenter: L G Ngwira, Malawi

The New $90-$90-$90: Drugs Affordable for All

Symposia Session WESY04
Time: 14:30 – 16:00  Venue: Blue Amphitheater
Co-Chairs: S Barton, UK and C Hankins, Netherlands

This multi-perspective session discusses and analyzes the barriers to global affordable drug pricing. It examines how therapeutics could become affordable, as currently, prices are variable worldwide and often high. The increasingly important role of advocacy, together with commitments by pharmaceuticals, originator and generic, for affordable therapeutics are debated and discussed in this session, allowing delegates to gain an understanding of issues related to the affordable pricing of essential medicines for HIV and comorbidities and the ability to identify the various forces shaping costs.

Visit our website http://www.who.int/tb/areas-of-work/tb-hiv/en/ and keep up to date with TB/HIV issues by following us on Twitter @HIVTB
**POSTER SESSIONS**

Posters Exhibition Area, Level 3, from 12:30 – 14:30 each day

**Poster Exhibition (Monday)**

**MOPEA0006**: Pre-existing TB infection and associated immune reconstitution inflammatory syndrome affects the HIV-1 reservoir. Presenter: C Lange, USA

**MOPEB0301**: Similar reduction of blood HIV-1 DNA reservoir with raltegravir and efavirenz in HIV-infected patients co-infected with TB. Presenter: H Delagrèverie, France

**MOPEB0340**: Eight weeks safety results of high-dose rifampicin in HIV-tuberculosis co-infected patients in Uganda: RIFAVIRENZ-ANRS 12292 trial. Presenter: D Atwine, Uganda

**MOPEB0357**: Isoniazid preventive therapy uptake among HIV-infected patients attending clinics in Southeastern Nigeria: a CQI initiative. Presenter: E Onu, Nigeria

**MOPEC0616**: Late diagnosis of HIV and shorter duration of antiretroviral drug exposure in HIV-infected mothers in PMTCT program, Mandalay, Myanmar. Presenter: T Hun, Myanmar

**MOPEC0684**: Tuberculosis intensified case finding among people living with HIV in Cote d’Ivoire: coverage, caveats and way forward. Presenter: A F Offoue, Cote d’Ivoire

**MOPED1119**: Successful results from TB/HIV integrated pilot model leading to national TB/HIV integration initiatives in Vietnam. Presenter: H Mai, Vietnam

**Poster Exhibition (Tuesday)**


**TUPEB0368**: Increasing TB case detection through the active case findings in selected slums project in Ajeromi local government are of Lagos state. Presenter: I Enwefah, Nigeria


**TUPEB0370**: TB diagnosis in HIV+ patients in Mozambique. A field study of combined point-of-care evaluation with GeneXpert, LAM and symptom screening. Presenter: F Cicciacci, Italy

**TUPEB0371**: Isoniazid preventive therapy uptake and completion in the era of differentiated HIV care. Presenter: K H Tram, USA

**TUPEB0373**: Feasibility of TB screening of unselected HIV-positive hospital admissions in sub-Saharan Africa: the STAMP trial. Presenter: A Gupta-Wright, UK

**TUPEB0374**: Distinct patterns of clinical characteristics in adult tuberculosis patients from urban compared to rural settings in Tanzania. Presenter: G Sikalengo, UR Tanzania

**TUPEB0375**: Mycobacterium tuberculosis lateral flow lipooparabinomannan assay (TB-LAM) and cryptococcal antigen lateral flow assay (CRAG LFA) as screening among patients with advanced HIV-disease in Conakry, Guinea. Presenter: L Ndayisenga, Belgium

**TUPEB0376**: Use and effects of pediatric isoniazid preventive therapy (IPT) in HIV-positive patients at the Baylor Clinical Center of Excellence (COE) in Mbabane, Swaziland. Presenter: A L Rosen-Gooding, USA

**TUPEB0377**: WHO four-symptom screening for tuberculosis in people living with HIV receiving antiretroviral therapy: a systematic review Presenter: Y Hamada, Switzerland

**TUPEB0379**: High mortality among HIV-positive patients with MDR-TB and second-line drug resistance reflects the urgent need for new drug regimens. Presenter: A Moore, South Africa

**TUPEB0380**: Usefulness of screening latent TB infection (LTBI) using interferon-gamma release assay and treating LTBI to prevent developing active TB in Korean HIV-infected patients: Presenter: S Lee, Korea

**TUPEB0471**: A diagnostic prediction model for tuberculosis treatment decision in smear and Xpert-negative HIV-infected children. Presenter: O Marcy, France

**TUPED1191**: Evaluation of lost to follow-up tracing system in integrated HIV care (IHC) program in Myanmar: call for strengthening current tracing activity. Presenter: S Thiha, Myanmar

**TUPED1196**: HIV and tuberculosis in Malawian prisons: a comprehensive prevention, screening and management programme. Presenter: S Mendelsohn, Belgium

**Poster Exhibition (Wednesday)**

**WEPEB0555**: Pharmacokinetics of Rifampin and Isoniazid during pregnancy and postpartum in South African women. Presenter: M V Schalkwyk, South Africa

**WEPEC0103**: Feasibility, uptake and yield of household-based TB active case finding within the combination prevention package in the HPTN 071 (PopART) intervention in high TB/HIV burden communities in South Africa. Presenter: B Yang, South Africa

**WEPED1462**: Stock-outs of antiretroviral and TB medicines in South Africa: a national cross-sectional survey. Presenter: B Hwang, Canada